The Vox Markets Podcast / Greg Madison of Shield Therapeutics: Agreement with Viatris enables opportunity to scale Accrufer® into a $2 billion market

View our embed guidelines

Sorry, your browser isn't supported.

We recommend upgrading to the latest Chrome, Firefox, Safari, or Edge.

You can visit our support center if you're having problems.